Search results
Results from the WOW.Com Content Network
Diagram depicting antibiotic resistance through alteration of the antibiotic's target site, modeled after MRSA's resistance to penicillin. Beta-lactam antibiotics permanently inactivate PBP enzymes, which are essential for cell wall synthesis and thus for bacterial life, by permanently binding to their active sites. Some forms of MRSA, however ...
Dukes' disease, named after Clement Dukes (1845–1925), [1] [2] also known as fourth disease, [3] Filatov-Dukes' disease (after Nil Filatov), [4] Staphylococcal Scalded Skin Syndrome (SSSS), [5] or Ritter's disease [6] is an exanthem (rash-causing) illness primarily affecting children and historically described as a distinct bacterial infection, though its existence as a separate disease ...
The diagnosis of vancomycin-resistant Staphylococcus aureus (VRSA) is performed by performing susceptibility testing on a single S. aureus isolate to vancomycin. This is accomplished by first assessing the isolate's minimum inhibitory concentration (MIC) using standard laboratory methods, including disc diffusion, gradient strip diffusion, and automated antimicrobial susceptibility testing ...
Neomycin/polymyxin B/bacitracin, also known as triple antibiotic ointment, is an antibiotic medication used to reduce the risk of infections following minor skin injuries. [1] [2] It contains the three antibiotics neomycin, polymyxin B, and bacitracin. [1] It is for topical use. [3] [4]
Linezolid is an antibiotic used for the treatment of infections caused by Gram-positive bacteria that are resistant to other antibiotics. [9] [10] Linezolid is active against most Gram-positive bacteria that cause disease, including streptococci, vancomycin-resistant enterococci (VRE), and methicillin-resistant Staphylococcus aureus (MRSA).
Vancomycin is a glycopeptide antibiotic medication used to treat certain bacterial infections. [7] It is administered intravenously (injection into a vein) to treat complicated skin infections, bloodstream infections, endocarditis, bone and joint infections, and meningitis caused by methicillin-resistant Staphylococcus aureus. [8]
Without antibiotic treatment, S. aureus bacteremia has a case fatality rate around 80%. [3] With antibiotic treatment, case fatality rates range from 15% to 50% depending on the age and health of the patient, as well as the antibiotic resistance of the S. aureus strain. [3]
However, staph infections are still prominent and a cause for concern among healthcare professionals, especially new antibiotic-resistant strains. In the U.S., the incidence of staph infection is around 38.2 to 45.7 per 100,000 person-years, whereas other First World countries have an average incidence rate of 10 to 30 per 100,000 person-years.